SCHEMBL343480

SCHEMBL343480

CC(C)(C)OC(=O)c1ccc(Nc2ncc3cnn(C4CCCCC4)c3n2)cc1

nearest known ligand 0.58

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
AURKA O14965 18/20 0.58
CDK1 P06493 18/20 0.58
CCNB1 P14635 15/20 0.58
AURKB Q96GD4 3/20 0.55
CDK4 P11802 2/20 0.52
CCND1 P24385 2/20 0.52
CCND3 P30281 2/20 0.52
CCNE1 P24864 1/20 0.52
CDK2 P24941 1/20 0.52
CDK6 Q00534 1/20 0.52
CYP3A4 P08684 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
CCND2 P30279 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1355934 0.86 AURKA (0.58) AURKACDK1CCNB1AURKBCDK4
SCHEMBL12639234 0.84 AURKA (0.62) AURKACDK1CCNB1AURKBCDK4
SCHEMBL1355769 0.84 AURKA (0.62) AURKACDK1CCNB1AURKBCDK4
SCHEMBL1356293 0.84 AURKA (0.60) AURKACDK1CCNB1AURKBCDK4
SCHEMBL12639344 0.83 CDK4 (0.69) AURKACDK1CCNB1AURKBCDK4
SCHEMBL1355734 0.83 CDK4 (0.69) AURKACDK1CCNB1AURKBCDK4
SCHEMBL12631934 0.82 AURKA (0.59) AURKACDK1CCNB1AURKBCDK4
SCHEMBL1355349 0.81 AURKA (0.64) AURKACDK1CCNB1AURKBCDK4
SCHEMBL12133460 0.80 CDK1 (0.67) AURKACDK1CCNB1AURKBCDK4
SCHEMBL12639083 0.80 CDK1 (0.57) AURKACDK1CCNB1AURKBCDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8637529-B2 Pyrazolo[3,4-d]pyrimidine compounds AbbYie Inc. (US) 2014-01-28 US claimed
US-20120015963-A1 NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-01-19 US claimed
US-8637529-B2 Pyrazolo[3,4-d]pyrimidine compounds AbbYie Inc. (US) 2014-01-28 US disclosed
US-20120015963-A1 NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-01-19 US disclosed
US-7947695-B2 Inhibitors of cell cycle kinases such as cyclin dependent kinase CDK4 and/or the Aurora kinases; use in combination with an anticancer agent JANSSEN PHARMACEUTICA NV (BE) 2011-05-24 US disclosed
US-7947695-B2 Inhibitors of cell cycle kinases such as cyclin dependent kinase CDK4 and/or the Aurora kinases; use in combination with an anticancer agent JANSSEN PHARMACEUTICA NV (BE) 2011-05-24 US disclosed
US-20080070914-A1 Inhibitors of cell cycle kinases such as cyclin dependent kinase CDK4 and/or the Aurora kinases; use in combination with an anticancer agent JANSSEN-CILAG (FR) 2008-03-20 US disclosed
US-20080070914-A1 Inhibitors of cell cycle kinases such as cyclin dependent kinase CDK4 and/or the Aurora kinases; use in combination with an anticancer agent JANSSEN-CILAG (FR) 2008-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015963-A1 NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS CHUK, MAP2K2, CDK3 AURKA 784/4885CDK1 10/4885CCNB1 388/4885
US-20080070914-A1 Inhibitors of cell cycle kinases such as cyclin dependent kinase CDK4 and/or the Aurora kinases; use in combination with an anticancer agent CDK1, CDK2, CDK4 AURKA 10/4885CDK1 1/4885CCNB1 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.